Table 1. Patient characteristics according to tumour stage.
| Local | Locally advanced | Metastasis | |
|---|---|---|---|
| Pancreatic cancer patients (n=79) | (n=26) | (n=19) | (n=34) |
| Male, n (%) | 12 (46.2) | 8 (42.1) | 20 (58.8) |
| Age (years), median (IQR) | 65 (59–70) | 58 (52–64) | 64 (57–68) |
| Localisation of primary tumour, n (%) | |||
| Caput | 20 (76.9) | 15 (78.9) | 18 (52.9) |
| Corpus | 0 (0) | 2 (10.5) | 4 (11.8) |
| Cauda | 1 (3.8) | 2 (10.5) | 10 (29.4) |
| Vater's papilla | 5 (19.2) | 0 (0) | 2 (5.9) |
| MP-TF activity (fM Xa min−1), median (IQR) | 46 (24–149) | 123 (41–181) | 328 (111–1184) |
| CA19–9 (kU l−1), median (IQR)a | 39 (9–374) | 1820 (72–3000) | 2139 (268–39 241) |
| Venous thromboembolism at inclusion, n (%) | 1 (3.8) | 0 (0) | 13 (38.2) |
| Overall survival (months), median (IQR) | 21.5 (11.9–41.6) | 6.9 (5.2–9.6) | 2.1 (1.1–4.7) |
| Death during follow-up, n (%) | 20 (76.9) | 19 (100) | 34 (100) |
| Flowcytometric subset analysis (n=55) | (n=11) | (n=16) | (n=28) |
| Total AnnV+MP (× 106 l−1), median (IQR) | 3204 (1677–5873) | 4114 (2600–6106) | 4249 (3118–6864) |
| AnnV+TF+MP (× 106 l−1), median (IQR) | 0 (0–40) | 0 (0–0) | 83 (0–307) |
| AnnV+MUC1+MP (× 106 l−1), median (IQR) | 0 (0–0) | 0 (0–282) | 152 (0–314) |
Abbreviations: IQR=interquartile range; MP=microparticle; TF=tissue factor; AnnV=Annexin V.
a
CA19–9, 6 missing values.